We thank Michelle Brackman, RN, for providing Joint Tissue Activity and Damage Examination (JADE) readings and Marlene Zepeda for creative editing of the JADE atlas. This study was supported by Health Resources and Services Administration service grant H30MC24045, Bioverativ (now Sanofi), and Pfizer. Dr Chang acknowledges support from the Veterans Affairs (grants I01CX001388 and I01RX002604). Dr von Drygalski has received honoraria for participating in scientific advisory board panels, consulting, and speaking engagements for Baxalta/Shire, Bayer, Bioverativ/Sanofi, CSL‐Behring, HemaBiologics, Novo Nordisk, and Pfizer. The JADE protocol has been copyrighted for licensure by the University of California San Diego. Dr von Drygalski is a cofounder and member of the Board of Directors of Hematherix, LLC, a biotech company that is developing superFactor V therapy for bleeding complications.
To read more please visit the website here.